miRNA Biomarkers in Multiple Sclerosis

The Potential Candidate miRNA Biomarkers in Multiple Sclerosis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04772495

Enrollment

Registered

2021-02-26

Start date

2015-05-31

Completion date

2017-07-31

Last updated

2021-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis, miRNA, Epigenetic, Biomarker

Keywords

Multiple sclerosis, miRNA biomarkers, peripheral blood molecular diagnostics

Brief summary

Multiple Sclerosis (MS) characterized by demyelination and axonal degeneration is a chronic inflammatory disease of the central nervous system (CNS). Recent studies have shown that dysregulated miRNAs alter immune responses, so they may have roles basis on various genetic diseases such as MS and may be potential targets for biomarkers and new therapeutic approaches. In this study, we evaluated the dysregulation of miRNA expression levels at MS and MS stages. We also discussed the potential of these miRNAs to be biomarkers and/or therapeutic targets in MS.

Interventions

GENETICmiRNA

miRNA effect on Multiple sclerosis pathology

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

25 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* The age of 25 years and above * at least one Central Nervous System (CNS) demyelination event

Exclusion criteria

* with genetic diseases, hypertension, head trauma, neuropsychiatric disease, diabetes mellitus, hypertension, cardiac failure, hepatic failure, renal failure, Thalassemia, Sickle cell disease, iron deficiency, and B12 deficiency

Design outcomes

Primary

Measure	Time frame	Description
miRNA expression	intraoperative	peripheral blood miRNA expressions

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026